Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Phase II results in RCC

Phase II results in RCC

Company Compound Patients Entry criteria CR PR Objective response (CR+PR) Stable disease Median survival Survival at timepoint Combination
Antigenics Oncophage (HSPPC-96) 61 Newly diagnosed stage IV metastatic RCC patients after nephrectomy

Read the full 360 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers